



# INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES

Published by JK Welfare &amp; Pharmascope Foundation

Journal Home Page: <https://ijrps.com>

## Effect of acetazolamide on morphometry of Wistar rat foetus central nervous system

Anuradha Mamidi\*<sup>1</sup>, Butchiraju Potturi<sup>1</sup>, Vijayraghavan R<sup>2</sup>, Rajesh Paluru<sup>3</sup><sup>1</sup>Department of Anatomy, Medici Institute of Medical Sciences, Ghanpur, Medchal, Telangana State, India<sup>2</sup>Department of Research, Saveetha University, Thandalam, Chennai, India<sup>3</sup>Department of Physiology, Medici Institute of Medical Sciences, Ghanpur, Medchal, Telangana State, India

### Article History:

Received on: 14.02.2018  
 Revised on: 21.05.2018  
 Accepted on: 26.05.2018

### Keywords:

Acetazolamide,  
 Wistar rats,  
 Teratogen,  
 Morphometry

### ABSTRACT

Present study elucidates the relation between dose-related defects and morphometry of the central nervous system in Wistar rat foetus. Brain measurements of the dorsal surface of 16-20 days old pregnant Wistar rats fetuses were measured by using Vernier callipers. Adult pregnant rats were randomly divided into two groups. Control group received 0.25ml of normal saline and treatment group received 80 & 160 mg/kg/b. Wt. of acetazolamide on 8<sup>th</sup>, 9<sup>th</sup> and 10<sup>th</sup> day of pregnancy respectively. Pregnancy was terminated on 16<sup>th</sup>, 18<sup>th</sup>, 20<sup>th</sup> day. All fetuses brain parameters were measured. Results show that high dose group rats were observed a significant reduction in all parameters when compared to control. Hence we can conclude that high doses may be neurotoxic to developing a nervous system of Wistar rats.



### \* Corresponding Author

Name: Dr. Anuradha Mamidi  
 Phone: +91- 8790747221  
 Email: anuradhamamidi1@gmail.com

ISSN: 0975-7538

DOI: <https://doi.org/10.26452/ijrps.v9i3.1565>

Production and Hosted by  
 IJRPS | <https://ijrps.com>  
 © 2018 | All rights reserved.

### INTRODUCTION

Acetazolamide is a carbonic anhydrase inhibitor, which is used to treat congestive heart failure, glaucoma, seizures, raised intraocular pressure, high altitude sickness and intracranial hypertension in humans (Bergstrom WH, 1952; Oles KS, 1989; Reiss WG, 1996; Supuran CT, 2015). However, many studies found that unilateral forelimb abnormalities particularly right side in experimental animals with the administration of acetazolamide (Layton, 1965; Wilson JG, 1968; Tellone CI, 1980; Scott WJ, 1981; Biddle FG, 1988; Beck SL, 1991).

The central nervous system malformations occur when teratogen is administered before or during the closure of the neural groove (Ezurumlu RA, 1982). Acetazolamide administration to pregnant mothers showed rare effects like sacroccygeal teratoma, metabolic acidosis, hypocalcemia, and hypomagnesemia in newborns. On crossing placental barrier renal tubular acidosis and low birth weight was found. A case study on maternal acetazolamide reported ectrodactyly and syndactyly at birth and oligodontia was noticed at 12yrs age. Pre-clinical studies on animals evidenced forelimb abnormalities, low fetal body weight with high doses indicating the drug as teratogenic. So if possible all drugs should be restricted in the first trimester due to drug-induced fetal teratogenicity.

A study done to know the relation between dose and response of acetazolamide on cerebral blood flow (CBF) and cerebral blood flow velocity (CBFV) determined that dose according to body weight and age should be considered, as the severity of side effects occur at a higher dose. As large doses of acetazolamide cross the blood-brain barrier and can dilate brain arterioles. Though there are reports of developmental toxicity of acetazolamide in laboratory animals, no morphometric study on

the teratogenic effect of acetazolamide on the spinal cord, cerebellum, and cerebrum of the fetuses reported (Grossmann WM, 2000; Ozawa H, 2001; Al-Saleem AI, 2016; Sethi HS, 2016; Arslan EK, 2016).

The present study focused on alterations in the measurements of foetal weight, crown rump length, tail length, brain weight, medial-anteroposterior diameter, lateral anteroposterior diameter, transverse diameter in the cerebrum, of fetuses following administration of acetazolamide to pregnant Wistar rats.

## MATERIAL AND METHODS

**Drug:** Acetazolamide pre-weighed 250mg available from commercial sources.

**Animals:** Nine adult Wistar female rats weighing about 170–250 gm were obtained from animal house Jeeva labs, Hyderabad. Three female rats were mated with one male overnight. The female rats were examined for sperms in the vaginal smear the next morning, and positive sperm ones were considered as 0.5 days pregnant. The pregnant rats were divided into two groups: (control and treatment group). The rats were kept under hygienic conditions, fed ad libitum and all had free access to water. This study is carried out in strict accordance with the recommendations detailed in the Guide for the Care and Use of Laboratory Animals and protocols are approved by the animal ethical committee.

### Intervention

Group-1 (control group): The rats were given 0.25 ml of normal saline orally on the 8<sup>th</sup>, 9<sup>th</sup>, and 10<sup>th</sup> days of the pregnancy. As per dosage, it is divided into two treatment Groups 60mg group-2 and 160 mg group-3 respectively. The rats received 80 and 160 mg/kg/b. Wt. of acetazolamide orally from 8<sup>th</sup>, 9<sup>th</sup> and 10<sup>th</sup> days of the pregnancy. The eighth-day rats which received acetazolamide 80 and 160 mg were terminated on the 16<sup>th</sup> day by ether inhalation. Similarly, 9<sup>th</sup> and 10<sup>th</sup> day rats were terminated on 18<sup>th</sup> and 20<sup>th</sup> day. Transverse abdominal incision removed fetuses and placentas.

All the fetuses were weighed and a ruler measured the crown-rump lengths. The fetuses were sacrificed with ether and examined for gross external malformation. A total of 81 fetuses (34 from the control group and 47 from the treatment group 80mg/kg/b. wt. -25litters, 160mg/kg/b. wt. -22 litters) were obtained.

### Methodology

Immediately after death, the heads were dissected through incisions along the dorsal aspect and the

dorsal cranial bones of the skull were removed to expose the brain, and immersed in 10% neutral buffered formal saline for 24 hours. After removal from the skull, the brain was blotted dry with a filter paper and weighed. The following brain measurements of the dorsal surface of 16- 20 days old Wistar rat fetuses were taken with the aid of Griffin Vernier callipers: cerebral lateral anteroposterior diameter (LAPD); cerebral medial anteroposterior diameter (MAPD); cerebral transverse diameter (TD).

### Statistical analysis

Performed using one-way analysis of variance (ANOVA) and experimental data are presented as mean+/- standard deviation (SD). For all the statistical analysis SPSS software was used.

P-Value < 0.05 were taken to be statistically significant.

## RESULTS

A total of 81 fetuses which include 34 from the control group and 47 from the treatment group (80mg/kg/b. wt. -25litters, 160mg/kg/b. wt. -22 litters) were obtained which were used for the morphometric study. The relation between dose-related defects and morphometry of the central nervous system on 8<sup>th</sup>, 9<sup>th</sup>, 10<sup>th</sup> day are given in Tables 1, 2, 3.

The Wistar rats were administered acetazolamide on the 8<sup>th</sup> day of pregnancy and divided into two groups based on dosage as 80 mg and 160mg groups and terminated on the 16<sup>th</sup> day of pregnancy. These groups were compared with the control group. The foetal weight (1.37±0.03; 1.20±0.02), crown-rump length (1.86±0.02; 1.79±0.04), tail length (0.76±0.03; 0.66±0.07) and brain weight (0.17±0.02; 0.19±0.03) of 80 mg and 160 mg groups were found respectively. These values were statistically significant with the control group foetal weight (2.45±0.07), crown-rump length (2.880.0±6), tail length (1.300.0±6) and brain weight (1.340.0±6).

The Wistar rats were administered acetazolamide on the 9<sup>th</sup> day of pregnancy and divided into two groups based on dosage as 80 mg and 160 mg groups and terminated on the 18<sup>th</sup> day of pregnancy. These groups were compared with the control group. The foetal weight (1.4±0.04; 1.20±0.04), crown-rump length (1.87±0.05; 1.83±0.01), tail length (0.78±0.09; 0.70±0.03) and brain weight (0.21±0.06; 0.23±0.01) of 80 mg and 160 mg groups were found respectively. These values were statistically significant with the control group foetal weight (2.4±0.11), crown-

**Table 1: Effect of acetazolamide on the 8th day of pregnancy in Wistar rats on foetal weight, crown-rump length, tail length and cerebral parameters**

Parameters	Control (Mean±SD)	Treatment (80mg/kg/b. wt.)(Mean±SD)	Treatment (160mg/kg/b. wt.) (Mean±SD)	F-value	P-value
Foetal-weight(gms)	2.45±0.07	1.37±0.03	1.20±0.02	1575.76	<.0001
Crown-rump Length cms)	2.88±0.06	1.86±0.02	1.79±0.04	1356.14	<.0001
Tail-length (cms)	1.30±0.06	0.76±0.03	0.66±0.07	338.23	<.0001
Brain -weight (gms)	1.34±0.06	0.17±0.02	0.19±0.03	1917.41	<.0001
Medial Anterior - Posterior diameter (cms)	0.57±0.05	0.51±0.07	0.42±0.02	18.85	<.0001
Lateral Anterior - posterior diameter (cms)	0.43±0.02	0.37±0.04	0.32±0.01	35.66	<.0001
Transverse diameter (cms)	0.65±0.04	0.59±0.08	0.47±0.04	21.98	<.0001

**Table 2: Effect of acetazolamide on the 9th day of pregnancy in Wistar rats on foetal weight, crown-rump length, tail length and cerebral parameters**

Parameters	Control (Mean±SD)	Treatment (80mg/kg/b. wt.)(Mean±SD)	Treatment (160mg/kg/b. wt.) (Mean±SD)	F-value	P-value
Foetal-weight(gms)	2.4 ± 0.11	1.4 ± 0.04	1.2 ± 0.04	658.3	<.0001
Crown-rump Length cms)	2.93±0.05	1.87±0.05	1.83 ± 0.01	1528.75	<.0001
Tail-length (cms)	1.29 ± 0.03	0.78 ± 0.09	0.70 ± 0.03	249.53	<.0001
Brain -weight (gms)	1.42 ± 0.05	0.21 ± 0.06	0.23 ± 0.01	1567.63	<.0001
Medial Anterior - Posterior diameter (cms)	0.57 ± 0.03	0.45±0.01	0.44±0.07	81.15	<.0001
Lateral Anterior - posterior diameter (cms)	0.43±0.03	0.41±0.04	0.33±0.01	74.66	<.0001
Transverse diameter (cms)	0.66±0.02	0.63±0.07	0.57±0.03	46.98	<.0001

rump length (2.93±0.05), tail length (1.29±0.03) and brain weight (1.42±0.05).

The Wistar rats were administered acetazolamide on the 10<sup>th</sup> day of pregnancy and divided into two groups based on dosage as 80 mg and 160mg groups and terminated on the 20<sup>th</sup> day of pregnancy. These groups were compared with the control group. The foetal weight (1.3±0.08; 1.20±0.04), crown-rump length (1.82±0.05; 1.82±0.01), tail length (0.74±0.03; 0.71±0.03) and brain weight (0.26±0.07; 0.23±0.01) of 80 mg and 160 mg groups were found respectively. These values were statistically significant with the control group foetal weight (2.4±0.04), crown-rump length (2.47±0.04), tail length (1.36±0.06) and brain weight (1.46±0.09).

The Wistar rats were administered acetazolamide on the 8<sup>th</sup> day of pregnancy and divided into two groups based on dosage as 80 mg and 160mg

groups and terminated on the 16<sup>th</sup> day of pregnancy. These groups were compared with the control group. The cerebrum, medial anteroposterior diameter (0.51±0.07; 0.42±0.02), lateral anteroposterior diameter (0.37±0.04; 0.32±0.01) and transverse diameter (0.59±0.08; 0.47±0.04) of 80mg and 160mg groups were found respectively. These values were statistically significant with the control group medial anteroposterior diameter (0.57±0.05), lateral anteroposterior diameter (0.43±0.02) and transverse diameter (0.65±0.04).

The Wistar rats were administered acetazolamide on the 9<sup>th</sup> day of pregnancy and divided into two groups based on dosage as 80 mg and 160mg groups and terminated on the 18<sup>th</sup> day of pregnancy. The cerebrum, medial anteroposterior diameter (0.45±0.01; 0.44±0.07), lateral anteroposterior diameter (0.41±0.05; 0.35±0.02)

**Table 3: Effect of acetazolamide on the 10th day of pregnancy in Wistar rats on foetal weight, crown-rump length, tail length and cerebral parameters**

Parameters	Control (Mean±SD)	Treatment (80mg/kg/b. wt.)(Mean±SD)	Treatment (160mg/kg/b. wt.)(Mean±SD)	F-value	P-value
Foetal-weight(gms)	2.4±0.04	1.3±0.08	1.2±0.04	1442.6	<.0001
Crown-rump Length cms)	2.47±0.04	1.82±0.05	1.82±0.01	781.94	<.0001
Tail-length (cms)	1.36±0.06	0.74±0.03	0.71±0.03	544.04	<.0001
Brain -weight (gms)	1.46±0.09	0.26±0.07	0.23±0.01	816.98	<.0001
Medial Anterior - Posterior diameter (cms)	0.63±0.06	0.45±0.01	0.44±0.07	54.86	<.0001
Lateral Anterior - posterior diameter (cms)	0.54±0.05	0.35±0.03	0.34±0.01	77.17	<.0001
Transverse diameter (cms)	0.68±0.04	0.68±0.06	0.54±0.01	26.66	<.0001

and transverse diameter (0.66±0.07; 0.57±0.04) of 80mg and 160mg groups were found respectively. These values were statistically significant with the control group medial anteroposterior diameter (0.57±0.03), lateral anteroposterior diameter (0.44±0.06) and transverse diameter (0.66±0.042).

The Wistar rats were administered acetazolamide on the 10<sup>th</sup> day of pregnancy and divided into two groups based on dosage as 80 mg and 160mg groups and terminated on the 20<sup>th</sup> day of pregnancy. The cerebrum, medial anteroposterior diameter (0.45±0.01; 0.44±0.07), lateral anteroposterior diameter (0.35±0.03; 0.34±0.02) and transverse diameter (0.68±0.06; 0.54±0.01) of 80mg and 160mg groups were found respectively. These values were statistically significant with the control group medial anteroposterior diameter (0.63±0.06), lateral anteroposterior diameter (0.54±0.05) and transverse diameter (0.68±0.04).

## DISCUSSION

To assess foetal growth and growth retardation body weight, crown-rump length, tail length has been commonly used as indices in experimental animals (Singh S, 1972; Lassen NA, 1987). According to many studies, it is found that there is a relation between malformations of the nervous system and various brain measurements. In cerebrum, lateral and medial, anteroposterior and transverse diameter were measured and found that these measurements are lower than the control group. It is in line with the line with studies related to developmental toxicity. These may be due to toxic effect exhibited on developing brain during neurulation (Crag BG, 1972; Singh S, 1978; Gutsaeva DR, 2004; Mesembe OE, 2004; Huang KC, 2006; Eluwa MA, 2009).

Earlier studies have observed acetazolamide has bi-directional influences on central nervous system oxygen toxicity. At low doses it would act as an anticonvulsant, under high doses oxidation of brain tissue increases due to increase in blood flow which causes central nervous system oxygen toxicity (Huang JL, 2010), it seems that large doses of acetazolamide cross the blood-brain barrier and dilate the brain arterioles. This might be the reason for the toxic effect on the brain (Grossmann WM, 2000; Ozawa H, 2001; Sethi HS, 2016; Arslan EK, 2016).

The results of this study revealed lower foetal body weight, crown-rump and tail lengths, medial anteroposterior diameter, lateral anteroposterior diameter, transverse diameter. These may indicate intrauterine growth retardation. This confirms that central nervous system malformations occur when teratogen is administered during the neurogenic period leading to developmental anomalies (Xu JH, 1996 Irigi AO, 1999).

The present study may prove that retarded intrauterine growth and fetal weight reduction with drug administration, is in line with previous research (Calvano C, 2000; Xu D, 2006). The foetal resorption was observed in 160mg/kg group and it may be due to the toxicity of acetazolamide and this finding is in line with previous research (Zhao L, 2008).

Morphometric methods may help to identify the difference between normal and severity of a disease. Magnetic resonance and imaging are widely used to find neuroanatomical, developmental and neurological disorders. In schizophrenia, autism, Alzheimer, dyslexia and Turner's syndrome shape of the brain are analyzed to correlate. In the present study brain weight,

cerebrum and cerebellar parameters were measured and compared with control to know the relation between day and dosage. The Present study is in line with previous research (Chandra Sekhar Rao T, 2015).

## CONCLUSION

High doses of acetazolamide may cause severe retardation in the development of the nervous system in Wistar rats fetuses as it has teratogenic property. Hence its use requires further evaluation.

**Acknowledgement:** I am thankful for Jeeva labs for the regular taking care of pregnant rats. Also, providing me with facilities for study.

**Conflicts of interest:** Nil

**Source of funding:** Nil.

## REFERENCES

- Al-Saleem, AL., Al-Jobair, AM. 2016. Possible association between acetazolamide administration during pregnancy and multiple congenital malformations. *Drug Des Devel Ther.* 10: 1471-1476.
- Arslan, EK., Kaplan, YC. 2016. Comment on the case report— the Possible association between acetazolamide administration during pregnancy and multiple congenital malformations. *Drug Des Devel Ther.* 10: 3681-3683.
- Beck, SL., Urbano, CM. 1991. Potentiating effect of caffeine on the teratogenicity of acetazolamide in C57BL/6J mice. *Teratology.* 44(3): 241-250.
- Bergstrom, WH., Carzoli, RF., Lombroso, C., Davidson, DT., Wallace, WM. 1952. Observations on metabolic and clinical effects of carbonic anhydrase inhibitors in epileptics. *Am J Dis Child.* 84: 71-73.
- Biddle, FG., 1988. Genetic differences in the frequency of acetazolamide-induced ectrodactyly in the mouse exhibit directional dominance of relative embryonic resistance. *Teratology.* 37(4): 375-388.
- Calvano, C., Hoar, R., Mankes, R., Lefevre, R., Reddy, P., Moran, M. 2000. Experimental study of umbilical cord length as a marker of fetal alcohol syndrome. *Teratology.* 61(3): 184-8.
- Chandra Sekhar Rao, T., Sreenivasulubrain, G. 2015. A Study of Status of Brain Morphometry Analysis in Neuroimaging images. *International Journal of Electronics and Communication Engineering.* 8 (1): 51-64.
- Cragg, BG. 1972. The development of cortical synapses during starvation in the rat. *Brain.* 95: 143-150.
- Eluwa, MA., Idumesaro, NB., Ekong, MB., Akpantah, AO., Ekanem, TB. 2009. Effect of aqueous extract of *Rauwolfia vomitoria* root bark on the cytoarchitecture of the cerebellar and neurobehavioral of adult male Wistar rats. *The Internet Journal of Alternative Medicine.* 6: 2.
- Erzurum, RA., Kilackey, HP. 1982. Critical and sensitive periods in Neurobiology: In *Current topics in Developmental Biology.* (17): 207-240.
- Grossmann, WM., Koeberle, B. 2000. The dose-response relationship of acetazolamide on the cerebral blood flow in normal subjects. *Cerebrovasc Dis.* 10(1):65-9.
- Gutsaeva, DR., Moskvin, AN., Zhiliaev Slu, Kostkin, VB., Demchenko, IT. 2004. Nitric oxide and carbon dioxide in neurotoxicity induced by oxygen under pressure. *Russ Fiziol Zh Im I M Sechenova.* 90: 428-436.
- Huang, KC., Hsu, WH., Peng, KT., Huang, TJ., Hsu, RW. 2006. Hyperbaric oxygen therapy in orthopaedic conditions: an evaluation of safety. *J Trauma.* 61: 913-917.
- Huang, JL., Zhang, YL., Xiao, X., Zhang, JH., Lian, QL., Liu, Y., Sun, XJ. 2010. Bidirectional influences of acetazolamide on central nervous system oxygen toxicity of rats. *Undersea & Hyperbaric Medicine; Bethesda.* 37(5): 271-80.
- Igiri, AO., Aniakot, IC., Osayande, O., Akpa, OA., Antia, Ud. 1999. Effect of halofantrine hydrochloride on the morphology and histology of the cerebral cortex of Wistar rat fetuses. *Mary Slessor Journal of Med.* 2 (1): 58-63.
- Lassen, NA., Friberg, L., Kastrup, J., Rizzi, D., Jensen, JJ. 1987. Effects of acetazolamide on cerebral blood flow and brain tissue oxygenation. *Postgraduate Medical Journal.* 63:185-187.
- Layton, WM., Jr, Hallesy, DW. 1965. Forelimb deformity in rats: association with acetazolamide. *Science.* 150 (3692):79.
- Mesembe, OE., Ivang, AE., Udofah, G., Igiri, AO., Eluwa, MA., Fisher, VA., Akpaso, Eluwa MA., Akpa, OA. 2004. A morphometric study of the teratogenic effect of artesunate on the central nervous system of Wistar rat fetus. *Nigerian Journal of Physiological Sciences.* (19) 1-2.
- Oles, KS., Penry, JK., Cole, DL., Howard, G. 1989. Use of acetazolamide as an adjunct to carbamazepine in refractory partial seizures. *Epilepsia.* 30: 74-78.
- Ozawa, H., Azuma, E., Shindo, K., Higashigawa, M., Mukouhara, R., Komada. 2001. Transient renal tubular acidosis in a neonate following trans

- placental acetazolamide. *Eur J Pediatr.* 160(5):321-2.
- Reiss, WG., Oles, KS.1996. Acetazolamide in the treatment of seizures. *Ann Pharmacother.* 30: 514-519.
- Scott, WJ., Hirsch. KS., DeSesso, JM., Wilson, JG.1981. Comparative studies on acetazolamide teratogenesis in pregnant rats, rabbits, and rhesus monkeys. *Teratology.* 24(1): 37-42.
- Sethi, HS., Naik, M., Gupta, VS.2016. Management of glaucoma in pregnancy: risks or choices, a dilemma? *International Journal of Ophthalmology.*9(11): 1684-1690.
- Singh, S., Sen Sharma, GC., Sangal, AK.1972. Malformations of the brain induced by Cyclophosphamide in rats. *Neurology India.* (3): 152-157.
- Singh, S., Padmanabhan, R.1978. Effect of Chlorpromazine (CPZ) in Developing rat brain: Morphological and Histological study. *Congenital Anomalies.* 18: 251-256.
- Supuran, CT.2015. Expert Rev Neurother Acetazolamide for the treatment of idiopathic intracranial hypertension. *Epub.* 715(8):851-6.
- Tellone, CI., Baldwin, JK., Sofia, RD.1980. Teratogenic activity in the mouse after oral administration of acetazolamide. *Drug Chem Toxicol.* 3(1):83-98.
- Wilson, JG., Maren, TH., Takano, K., Ellison.1968. Teratogenic action of carbonic anhydrase inhibitors in the rat. *Teratology.* 1:51-60.
- Xu, D., Chen, Y., Zhao, L., Wang, H., Wei, W.2006. Reactive oxygen species are involved in lipopolysaccharide-induced intrauterine growth restriction and skeletal development retardation in mice. *Am J Obstet Gynecol.* 195(6):1707-14.
- Xu, JH., Zhang, YP.1996. Contra gestational effects of dihydroartemisinin and artesunate. *Yao Xue Bao.* 31(9): 657-61.
- Zhao, L., Chen, Y., Wang, H., Ji, Y., Ning, H., Wang, S., et al.2008. Reactive oxygen species contribute to lipopolysaccharide-induced teratogenesis in mice. *Toxicol Sci.* 103(1):149-57.